Skip to main content
Year archive

Oncopeptides — 2019 filings

All 62 regulatory filings released by Oncopeptides (ONCO) in 2019, sourced directly from the official regulator.

62 Filings
2019 Period
2019 filings (62)
Filing Released Lang
Bulletin from the Extraordinary General Meeting in Oncopeptides AB (publ)
AGM Information
2019-12-17 English
Kommuniké från Extra bolagsstämma i Oncopeptides AB (publ)
Share Issue/Capital Change
2019-12-17 Swedish
Oncopeptides presents promising data from the Phase 2 ANCHOR combination study in patients with RRMM at ASH Annual Meeting 2019
Investor Presentation
2019-12-09 English
Oncopeptides presenterar lovande data från fas 2-kombinationsstudien ANCHOR i patienter med RRMM vid ASH:s årsmöte 2019
Regulatory Filings
2019-12-09 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report Q3 2019
2019-11-19 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report 9M 2019
2019-11-19 English
Extra bolagsstämma i Oncopeptides AB (publ)
AGM Information
2019-11-14 English
Extraordinary General Meeting in Oncopeptides AB (publ)
AGM Information
2019-11-14 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-11-08 English
Number of shares and votes in Oncopeptides
Share Issue/Capital Change
2019-10-31 English
Antal aktier och röster i Oncopeptides
Declaration of Voting Results & Voting Rights Announcements
2019-10-31 Swedish
Valberedning utsedd inför årsstämma 2020 i Oncopeptides
Governance Information
2019-10-10 Swedish
Nomination Committee appointed in respect of AGM 2020 in Oncopeptides
AGM Information
2019-10-10 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-10-10 English
Number of shares and votes in Oncopeptides
Share Issue/Capital Change
2019-09-30 English
Antal aktier och röster i Oncopeptides
Share Issue/Capital Change
2019-09-30 Swedish
Exercise of options and sale of shares under the Employee Stock Option Program 2012/2019
Share Issue/Capital Change
2019-09-24 English
Utnyttjande av optioner och försäljning av aktier under Personaloptionsprogram 2012/2019
Share Issue/Capital Change
2019-09-24 Swedish
Nya interimsdata i RRMM-patienter med metastaserad cancer (EMD) från den pivotala fas 2-studien HORIZON presenteras på International Myeloma Workshop
Regulatory Filings
2019-09-15 Swedish
New Interim Data in RRMM Patients with Extramedullary Disease from the Pivotal Phase 2 Horizon-study presented at International Myeloma Workshop
Regulatory Filings
2019-09-15 English
Interim / Quarterly Report 2019
Interim / Quarterly Report Q2 2019
2019-08-28 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report Q2 2019
2019-08-28 English
Oncopeptides appoints Klaas Bakker as new Chief Medical Officer
Board/Management Information
2019-08-20 English
Oncopeptides utser Klaas Bakker som ny Chief Medical Officer
Board/Management Information
2019-08-20 Swedish
Antal aktier och röster i Oncopeptides
Declaration of Voting Results & Voting Rights Announcements
2019-07-31 Swedish
Number of shares and votes in Oncopeptides
Share Issue/Capital Change
2019-07-31 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-07-04 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-07-01 English
Oncopeptides har genomfört en riktad nyemission om cirka 727 miljoner kronor
Capital/Financing Update
2019-06-28 Swedish
Oncopeptides has completed a directed share issue of approximately SEK 727 million
Capital/Financing Update
2019-06-28 English
Oncopeptides avser att genomföra en riktad nyemission
Capital/Financing Update
2019-06-27 Swedish
Oncopeptides intends to make a directed share issue
Capital/Financing Update
2019-06-27 English
Nya data presenterade från Oncopeptides pivotala fas 2-studie HORIZON med melflufen i RRMM-patienter vid det 24:e europeiska hematologimötet (EHA)
Earnings Release FY 2019
2019-06-16 Swedish
New Data Presented from Oncopeptides’ Pivotal Phase 2 HORIZON Trial Evaluating Melflufen in Relapsed/Refractory Multiple Myeloma at 24th EHA Congress
Earnings Release FY 2019
2019-06-16 English
New Data Presented at 24th EHA Congress from Oncopeptides’ Phase 1/2 ANCHOR Trial Evaluating Melflufen in Relapsed/Refractory Multiple Myeloma (RRMM)
Regulatory Filings
2019-06-14 English
Oncopeptides presenterar nya data från fas 1/2-studien ANCHOR med melflufen i RRMM-patienter vid det 24:e europeiska hematologimötet (EHA)
Earnings Release FY 2019
2019-06-14 Swedish
KOMMUNIKÉ FRÅN ÅRSSTÄMMA I ONCOPEPTIDES AB (PUBL)
AGM Information
2019-05-21 Swedish
BULLETIN FROM THE ANNUAL GENERAL MEETING IN ONCOPEPTIDES AB (PUBL)
AGM Information
2019-05-21 English
Interim / Quarterly Report 2019
Interim / Quarterly Report Q1 2019
2019-05-21 English
Interim / Quarterly Report 2019
Interim / Quarterly Report Q1 2019
2019-05-21 Swedish
Oncopeptides kommer att ansöka om villkorat marknadsgodkännande i USA
Regulatory Filings
2019-05-20 Swedish
Oncopeptides to Apply for Accelerated Approval in the US
Regulatory Filings
2019-05-20 English
Oncopeptides Announces Acceptance of Four Abstracts Highlighting Melflufen Clinical Programs for Presentation at 24th EHA Congress in June 2019
Regulatory Filings
2019-05-16 English
Oncopeptides meddelar att fyra abstrakt gällande melflufens kliniska program godkänts för presentation vid den 24:e EHA-kongressen i juni 2019
Regulatory Filings
2019-05-16 Swedish
Oncopeptides meddelar att melflufen-data har accepterats för presentation vid ASCO:s årsmöte i juni 2019
AGM Information
2019-05-15 Swedish
Oncopeptides Announces Melflufen Data Accepted for Presentation at 2019 ASCO Annual Meeting
Regulatory Filings
2019-05-15 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-05-02 English
Annual Report 2018
Annual Report FY 2018
2019-04-26 Swedish
Annual Report 2018
Annual Report FY 2018
2019-04-26 English
Oncopeptides kommer att ge ny vägledning om patientrekrytering i OCEAN-studien och en klinisk programuppdatering i en webbsändning klockan 10:00 (CET)
Earnings Release FY 2019
2019-04-24 Swedish
Oncopeptides provides new guidance on the patient recruitment in the OCEAN study and a clinical program update in a webcast at 10:00 (CET)
Regulatory Filings
2019-04-24 English
ÅRSSTÄMMA I ONCOPEPTIDES AB (PUBL)
AGM Information
2019-04-16 Swedish
ANNUAL GENERAL MEETING IN ONCOPEPTIDES AB (PUBL)
AGM Information
2019-04-16 English
Earnings Release 2018
Earnings Release Q4 2018
2019-02-22 Swedish
Interim / Quarterly Report 2018
Interim / Quarterly Report FY 2018
2019-02-22 English
Antal aktier och röster i Oncopeptides
Declaration of Voting Results & Voting Rights Announcements
2019-01-31 Swedish
Number of shares and votes in Oncopeptides
Declaration of Voting Results & Voting Rights Announcements
2019-01-31 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-01-30 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-01-28 English
Oncopeptides has completed a directed share issue of approximately SEK 546 million
Capital/Financing Update
2019-01-24 English
Oncopeptides har genomfört en riktad nyemission om cirka 546 miljoner kronor
Share Issue/Capital Change
2019-01-24 Swedish
Oncopeptides avser att genomföra en riktad nyemission
Share Issue/Capital Change
2019-01-23 Swedish